Adenosine A2A receptors and depression

Neurology

Volumn 61, Issue 11 SUPPL. 6, 2003, Pages

  El Yacoubi, Malika ^a   Costentin, Jean ^a   Vaugeois, Jean Marie ^a  

^a IFRMP 23   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; CAFFEINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; ISTRADEFYLLINE; ADENOSINE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIDEPRESSANT AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TRIAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG RECEPTOR BINDING; FORCED SWIMMING TEST; FRONTAL CORTEX; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DRUG ANTAGONISM; DRUG INTERACTION; METABOLISM; MOTOR ACTIVITY; MOUSE MUTANT; PARKINSONISM; PATHOPHYSIOLOGY;

ADENOSINE; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CAFFEINE; DEPRESSION; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; HALOPERIDOL; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; NEUROTRANSMITTER AGENTS; PARKINSONIAN DISORDERS; PURINES; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; TRIAZINES; TRIAZOLES;

EID: 0345600929     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000095220.87550.f6     Document Type: Article

References (58)

1. Dunwiddie TV, Fredholm BB. Adenosine neuromodulation. In: Jacobson KA, Jarvis MF, eds. Purinergic Approaches in Experimental Therapeutics. New York: Wiley-Liss, 1997:359-382.
2. Stiles GL. Adenosine receptor subtypes: new insights from cloning and functional studies. In: Jacobson KA, Jarvis MF, eds. Purinergic Approaches in Experimental Therapeutics. New York: Wiley-Liss, 1997:29-37.
3. Jain N, Kemp N, Adeyemo O, Buchanan P, Stone TW. Anxiolytic activity of adenosine receptor activation in mice. Br J Pharmacol 1995;116:2127-2133.
4. 2A adenosine receptor antagonists. Psychopharmacology 2000;148:153-163.
5. 2A receptor. Nature 1997;388:674-678.
6. Porkka-Heiskanen T. Adenosine in sleep and wakefulness. Ann Med 1999;31:125-129.
7. Snyder SH, Katims JJ, Annau Z, Bruns RF, Daly JW. Adenosine receptors and behavioral actions of methylxanthines. Proc Natl Acad Sci USA 1981;78:3260-3264.
8. Fredholm BB. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol 1995;76:93-101.
9. Fredholm BB, Bättig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51:83-133.
10. 2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience 1997;79:753-764.
11. 2A receptors. Br J Pharmacol 2000;129:1465-1473.
12. Willner P. Dopaminergic mechanisms in depression and mania. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995:921-931.
13. Fibiger HC. Neurobiology of depression: focus on dopamine. In: Gessa G, Fratta W, Pani L, Serra G, eds. Depression and Mania: From Neurobiology to Treatment. New York: Raven Press, 1995:1-17.
14. Drevets WC. Functional neuroimaging studies of depression: the anatomy of melancholia. Annu Rev Med 1998;49:341-361.
15. Minor TR, Winslow JL, Chang WC. Stress and adenosine: II. Adenosine analogs mimic the effect of inescapable shock on shuttle-escape performance in rats. Behav Neurosci 1994;108:265-276.
16. Woodson JC, Minor TR, Job RF. Inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine(EHNA)mimics the effect of inescapable shock on escape learning in rats. Behav Neurosci 1998;112:399-409.
17. Porsolt RD, Bertin A, Jalfre M. Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-336.
18. Kulkarni SK, Mehta AK. Purine nucleoside-mediated immobility in mice: reversal by antidepressants. Psychopharmacology 1985;85:460-463.
19. 2A receptors. Drug Dev Res 1996;39:450-460.
20. Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997;20:482-487.
21. 2A receptors. Trends Pharmacol Sci 1996;17:364-372.
22. Svenningsson P, Hall H, Sedvall G, Fredholm BB. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse 1997;27:322-335.
23. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-513.
24. 2A antagonists in PD. Neurology 2002;58:1154-1160.
25. D'haenen HA, Bossuyt A. Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry 1994;35:128-132.
26. Laasonen-Balk T, Kuikka J, Viinamäki H, Husso-Saastamoinen M, Lehtonen J, Tiihonen J. Striatal dopamine transporter density in major depression. Psychopharmacology 1999;144:282-285.
27. Cooper BR, Hester TJ, Maxwell RA. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin(D): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 1980;215:127-134.
28. Davidson JR, Connor KM. Bupropion sustained release: a therapeutic overview. J Clin Psychiatry 1998;59:25-31.
29. Post RM, Gerner RH, Carman JS, et al. Effects of a dopamine agonist piribedil in depressed patients. Arch Gen Psychiatry 1978;35:609-615.
30. Colonna L, Petit M, Lépine JP. Bromocriptine in affective disorders. J Affect Dis 1979;1:173-177.
31. Stéru L, Chermat R, Thierry B, et al. The automated tail suspension test: a computerized device which differentiates psychotropic drugs. Prog Neuropsychopharmacol Biol Psychiatry 1987;11:659-671.
32. Porsolt RD, McArthur RA, Lenègre A. Psychotropic screening procedures. In: Van Haaren F, ed. Methods in Behavioral Pharmacology. Amsterdam: Elsevier, 1993:23-51.
33. Perrault G, Morel E, Zivkovic B, Sanger DJ. Activity of litoxetine and other serotonin uptake inhibitors in the tail suspension test in mice. Pharmacol Biochem Behav 1992;42:45-47.
34. Borsini F, Pulvirenti L, Samanin R. Evidence of dopamine involvement in the effect of repeated treatment with various antidepressants in the behavioural 'despair' test in rats. Eur J Pharmacol 1985;110:253-256.
35. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999;19:9192-9200.
36. 2a double knockout mice. Eur J Neurosci 2003;17:315-324.
37. Tucker JC, File SE. The effects of tricyclic and 'atypical' antidepressants on spontaneous locomotor activity in rodents. Neurosci Biobehav Rev 1986;10:115-121.
38. Boulay D, Depoortere R, Perrault G, Borelli E, Sanger DJ. Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists. Neuropharmacology 1999;38:1389-1396.
39. Borsini F, Lecci A, Mancinelli A, D'aranno V, Meli A. Stimulation of dopamine D-2 but not D-1 receptors reduces immobility time of rats in the forced swimming test: implication for antidepressant activity. Eur J Pharmacol 1988;148:301-307.
40. Sarges R, Howard HR, Browne RG, Lebel LA, Seymour PA, Koe BK. 4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. J Med Chem 1990;33:2240-2254.
41. Jacobson KA, Van Rhee M. Development of selective purinoceptor agonists and antagonists. In: Jacobson KA, Jarvis MF, eds. Purinergic Approaches in Experimental Therapeutics. New York: Wiley-Liss, 1997:101-128.
42. Svenningsson P, Nomikos GG, Fredholm BB. Biphasic changes in locomotor behavior and in expression of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration. J Neurosci 1995;15:7612-7624.
43. Schechter MD, Chance WT. Non-specificity of "behavioral despair" as an animal model of depression. Eur J Pharmacol 1979;60:139-142.
44. Seeman P. Brain dopamine receptors. Pharmacol Rev 1980;32:229-313.
45. 2 dopamine receptor antagonists block caffeine-induced stimulation of locomotor activity in rats. Pharmacol Biochem Behav 1994;47:89-94.
46. Goldberg MR, Curatolo PW, Tung CS, Robertson D. Caffeine down-regulates beta adrenoreceptors in rat forebrain. Neurosci Lett 1982;31:47-52.
47. West CHK, Weiss JM. Effects of antidepressant drugs on rats bred for low activity in the swim test. Pharmacol Biochem Behav 1998;61:67-79.
48. Ongini E, Dionisotti S, Gessi S, Irenius E, Fredholm BB. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 1999;359:7-10.
49. Shiozaki S, Ishikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 1999;147:90-95.
50. 2A receptor knockout mice. Br J Pharmacol 2001;134:68-77.
51. Vaugeois J-M, Odievre C, Loisel L, Costentin J. A genetic mouse model of helplessness sensitive to imipramine. Eur J Pharmacol 1996;316: R1-R2.
52. Borsini F, Meli A. The forced swimming test: its contribution to the understanding of the mechanisms of action of antidepressants. In: Gessa GL, Serra G, eds. Dopamine and Mental Depression. Oxford: Pergamon Press, 1990:63-76.
53. 2A receptor antagonist with anticataleptic activity. Eur J Pharmacol 1994;256:263-268.
54. Tanda G, Carboni E, Frau R, Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology 1994;115:285-288.
55. Deutch AY, Roth RH. The determinants of stress-induced activation of the prefrontal cortical dopamine system. Prog Brain Res 1990;85:367-403.
56. Moghaddam B, Bunney BS. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 1990;54:1755-1760.
57. Johansson B, Georgiev V, Kuosmanen T, Fredholm BB. Long-term treatment with some methylxanthines decreases the susceptibility to bicuculline-and pentylenetetrazol-induced seizures in mice. Eur J Neurosci 1996;762:153-164.
58. Cools AR. Role of the neostriatal dopaminergic activity in sequencing and selecting behavioural strategies: facilitation of processes involved in selecting the best strategy in a stressful situation. Behav Brain Res 1980;1:361-378.